Vanessa K Hinson1, Amy Delambo1, Jordan Elm2, Travis Turner1. 1. Department of Neurology Medical University of South Carolina Charleston South Carolina USA. 2. Division of Biostatistics and Epidemiology Medical University of South Carolina Charleston South Carolina USA.
Abstract
BACKGROUND: Mild cognitive impairment in Parkinson's disease (PD-MCI) is associated with diminished norepinephrine from the locus coeruleus to the prefrontal cortex. Atomoxetine is a specific norepinephrine reuptake inhibitor that has been approved by the US Food and Drug Administration to treat attention deficit hyperactivity disorder in adults. The authors hypothesized that atomoxetine would improve attention and executive functioning in patients with PD-MCI. METHODS: Thirty participants who met Movement Disorder Society Task Force Level I criteria for PD-MCI were enrolled in a randomized controlled trial of atomoxetine. Cognitive evaluations were performed at baseline and after 10 weeks of treatment or placebo. A safety visit was performed at Week 12. A global statistical test was used to examine treatment effects on standardized tests of attention, working memory, processing speed, and set shifting (primary outcome measure). Secondary outcomes included cognitive measures hypothesized to be insensitive to atomoxetine, the Conners Adult Attention Deficit Hyperactivity Disorder Rating Scale, and safety measures. RESULTS: Fifteen participants were randomized to each arm. Groups were similar on medical and demographic variables and baseline cognition. Three serious adverse events occurred; 2 on atomoxetine (syncope, isolated episode of atrial fibrillation) and 1 on placebo (atrial fibrillation). The global statistical test of primary outcome measures did not reveal a significant difference between groups. However, significant improvements were observed for atomoxetine but not placebo on subjective measures of attention and impulsivity (Conners Adult Attention Deficit Hyperactivity Disorder Rating Scale). CONCLUSIONS: Atomoxetine treatment produced subjective, but not objective, improvements in PD-MCI. Failure to detect objective differences may be due to insensitivity of cognitive tests or severity of cognitive deficits in the study participants.
BACKGROUND: Mild cognitive impairment in Parkinson's disease (PD-MCI) is associated with diminished norepinephrine from the locus coeruleus to the prefrontal cortex. Atomoxetine is a specific norepinephrine reuptake inhibitor that has been approved by the US Food and Drug Administration to treat attention deficit hyperactivity disorder in adults. The authors hypothesized that atomoxetine would improve attention and executive functioning in patients with PD-MCI. METHODS: Thirty participants who met Movement Disorder Society Task Force Level I criteria for PD-MCI were enrolled in a randomized controlled trial of atomoxetine. Cognitive evaluations were performed at baseline and after 10 weeks of treatment or placebo. A safety visit was performed at Week 12. A global statistical test was used to examine treatment effects on standardized tests of attention, working memory, processing speed, and set shifting (primary outcome measure). Secondary outcomes included cognitive measures hypothesized to be insensitive to atomoxetine, the Conners Adult Attention Deficit Hyperactivity Disorder Rating Scale, and safety measures. RESULTS: Fifteen participants were randomized to each arm. Groups were similar on medical and demographic variables and baseline cognition. Three serious adverse events occurred; 2 on atomoxetine (syncope, isolated episode of atrial fibrillation) and 1 on placebo (atrial fibrillation). The global statistical test of primary outcome measures did not reveal a significant difference between groups. However, significant improvements were observed for atomoxetine but not placebo on subjective measures of attention and impulsivity (Conners Adult Attention Deficit Hyperactivity Disorder Rating Scale). CONCLUSIONS: Atomoxetine treatment produced subjective, but not objective, improvements in PD-MCI. Failure to detect objective differences may be due to insensitivity of cognitive tests or severity of cognitive deficits in the study participants.
Authors: Kallol Ray Chaudhuri; Pablo Martinez-Martin; Richard G Brown; Kapil Sethi; Fabrizio Stocchi; Per Odin; William Ondo; Kazuo Abe; Graeme Macphee; Doug Macmahon; Paolo Barone; Martin Rabey; Alison Forbes; Kieran Breen; Susanne Tluk; Yogini Naidu; Warren Olanow; Adrian J Williams; Sue Thomas; David Rye; Yoshio Tsuboi; Annette Hand; Anthony H V Schapira Journal: Mov Disord Date: 2007-10-15 Impact factor: 10.338
Authors: C G Ballard; D Aarsland; I McKeith; J O'Brien; A Gray; F Cormack; D Burn; T Cassidy; R Starfeldt; J-P Larsen; R Brown; M Tovee Journal: Neurology Date: 2002-12-10 Impact factor: 9.910
Authors: Emily Rosenthal; Laura Brennan; Sharon Xie; Howard Hurtig; Joshua Milber; Daniel Weintraub; Jason Karlawish; Andrew Siderowf Journal: Mov Disord Date: 2010-07-15 Impact factor: 10.338
Authors: Michael Lawton; Meike Kasten; Margaret T May; Brit Mollenhauer; Martina Schaumburg; Inga Liepelt-Scarfone; Walter Maetzler; Eva-Juliane Vollstedt; Michele T M Hu; Daniela Berg; Yoav Ben-Shlomo Journal: Mov Disord Date: 2016-02-10 Impact factor: 10.338
Authors: Claire O'Callaghan; Frank H Hezemans; Rong Ye; Catarina Rua; P Simon Jones; Alexander G Murley; Negin Holland; Ralf Regenthal; Kamen A Tsvetanov; Noham Wolpe; Roger A Barker; Caroline H Williams-Gray; Trevor W Robbins; Luca Passamonti; James B Rowe Journal: Brain Date: 2021-09-04 Impact factor: 13.501
Authors: Dag Aarsland; Lucia Batzu; Glenda M Halliday; Gert J Geurtsen; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub Journal: Nat Rev Dis Primers Date: 2021-07-01 Impact factor: 52.329
Authors: Frank H Hezemans; Noham Wolpe; Claire O'Callaghan; Rong Ye; Catarina Rua; P Simon Jones; Alexander G Murley; Negin Holland; Ralf Regenthal; Kamen A Tsvetanov; Roger A Barker; Caroline H Williams-Gray; Trevor W Robbins; Luca Passamonti; James B Rowe Journal: PLoS Comput Biol Date: 2022-05-09 Impact factor: 4.779
Authors: Qiang Zhang; Georgina M Aldridge; Nandakumar S Narayanan; Steven W Anderson; Ergun Y Uc Journal: Neurotherapeutics Date: 2020-11-17 Impact factor: 6.088
Authors: Jennifer G Goldman; Leah K Forsberg; Bradley F Boeve; Melissa J Armstrong; David J Irwin; Tanis J Ferman; Doug Galasko; James E Galvin; Daniel Kaufer; James Leverenz; Carol F Lippa; Karen Marder; Victor Abler; Kevin Biglan; Michael Irizarry; Bill Keller; Leanne Munsie; Masaki Nakagawa; Angela Taylor; Todd Graham Journal: Alzheimers Res Ther Date: 2020-10-29 Impact factor: 6.982